Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the …
Full DCTH analysis →
Competitive advantage assessment
Key strengths
Strong FCF GenerationFCF margin quality is top-tier vs peers (score 0.97). High FCF conversion confirms strong earnings quality.
Elite Gross MarginsGross margin quality is top-tier vs peers (score 0.94). This signals strong consumable attach-rate economics.
Delcath Systems, Inc. ranks #19 of 160
scored companies in Medical Devices by moat score — the top 12%.
The widest moat in the group is iRadimed Corporation (IRMD)
at 83/100.
Moat scores for companies ranked near DCTH in Medical Devices
How DCTH scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 69
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 46
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 96
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 84
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 46
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 91
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Delcath Systems, Inc. (DCTH) scores 71 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #19 of 160 scored companies in Medical Devices, the top 12%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is FCF Quality & Cash Conversion (96/100) and its weakest is Capital Structure & Resilience (46/100).
How does Delcath Systems, Inc. compare with other Medical Devices companies?
Delcath Systems, Inc. ranks #19 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are LivaNova PLC (LIVN) at 72 just above it and Semler Scientific, Inc. (SMLR) at 70 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.
Why is Delcath Systems, Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Delcath Systems, Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and DCTH scores: Pricing Power & Consumable Moat (69), R&D Pipeline & Capital Returns (46), FCF Quality & Cash Conversion (96), Commercial Execution (84), Capital Structure & Resilience (46), Growth Durability (91). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.